Skip to main content

Table 2 Baseline clinical and pathological characteristics of validation cohort A

From: New risk score for predicting steroid resistance in patients with focal segmental glomerulosclerosis or minimal change disease

Clinical variable No responseResponseOR (95% CI)a
N (%) 54 (34.4)103 (65.6)
Age (year) 34.7 ± 14.734.3 ± 15.31.005 (0.98–1.03)
Gender (male %) 37 (68.5)60 (58.3)0.62 (0.31–1.27)
MAP (mmHg) 95.4 ± 16.592.7 ± 11.91.02 (0.99–1.04)
BMI (kg/m2) 24.4 ± 3.723.7 ± 3.71.04 (0.94–1.14)
Ln(Pro) (g/24 h) 1.8 ± 0.41.8 ± 0.41.17 (0.52–2.60)
Albumin (g/L) 16.5 ± 6.816.1 ± 5.61.01 (0.96–1.07)
eGFR (mL/min/1.73 m2) 81.9 ± 37.599.1 ± 27.50.98 (0.97–0.99)#
TG (mmol/L) 4.3 ± 3.93.6 ± 3.41.05 (0.96–1.16)
TC (mmol/L) 10.6 ± 3.610.5 ± 4.11.001 (0.92–1.09)
Ln(β2-MG/uCr) (ug/mmoL) 4.6 ± 1.73.2 ± 1.51.76 (1.30–2.37)#
Pathological evaluationScoreNo responseResponseOR (95% CI)
FSGS (%) 46 (45.5)55 (54.5)5.02(2.16–11.7)#
MCD (%) 8 (14.3)48 (85.7)0.20(0.09–0.46)#
Global sclerosis (%)027 (50.0)74 (71.8)-ref-
123 (42.6)28 (27.2)2.25(1.11–4.56)*
Segmental sclerosis (%)010 (18.5)59 (57.3)-ref-
140 (74.1)43 (41.7)5.49(2.47–12.17)#
Interstitial fibrosis (%)08 (14.8)43 (35.0)-ref-
142 (77.8)59 (57.3)3.83(1.63–8.97)#
Inflammatory cell infiltration (%)014 (25.9)47 (45.6)-ref-
136 (66.7)55 (53.4)2.20(1.06-–4.56)*
Tubular atrophy (%)012 (22.2)46 (44.7)-ref-
138 (70.4)56 (54.4)2.60(1.22–5.55)*
Vascular lesion (%)029 (53.7)62 (60.2)-ref-
120 (37.0)40 (38.8)1.07 (0.53–2.14)
  1. MAP: mean arterial pressure; BMI: body mass index; Ln(Pro): natural logarithm of urine protein; eGFR: estimated glomerular filtration rate; TG: triglyceride; TC: total cholesterol; β2-MG: β2-microglobulin; α1-MG: α1-microglobulin; uCr: urinary creatinine; FSGS: focal segmental glomerulosclerosis; MCD: minimal change disease; IgAN: Immunoglobulin A nephropathy; MN: membranous nephropathy
  2. a Adjusted by age and gender
  3. *P < 0.05, #P < 0.01